Antineoplastic therapy-induced pulmonary toxicity

References

• Martin WJ 2nd, Rosenow EC 3rd. Amiodarone pulmonary toxicity. Recognition and pathogenesis (part 2). Chest 93(6), 1242–1248 (1988).
   PubMed Web of Science ®Google Scholar
• Hainer BL, White AA. Nitrofurantoin pulmonary toxicity. J. Fam. Pract. 13(6), 817–823 (1981).
   PubMedGoogle Scholar
• Naito Y, Tsuchiya S, Ishihara S et al. Impact of preexisting pulmonary fibrosis detected on chest radiograph and CT on the development of gefitinib-related interstitial lung disease. Am. J. Clin. Oncol. 31(4), 340–344 (2008).
   PubMedGoogle Scholar
• Cisneros-Lira J, Gaxiola M, Ramos C, Selman M, Pardo A. Cigarette smoke exposure potentiates bleomycin-induced lung fibrosis in guinea pigs. Am. J. Physiol. Lung Cell Mol. Physiol. 285(4), L949–L956 (2003).
   Google Scholar
• Geara FB, Komaki R, Tucker SL, Travis EL, Cox JD. Factors influencing the development of lung fibrosis after chemoradiation for small cell carcinoma of the lung: evidence for inherent interindividual variation. Int. J. Radiat. Oncol. Biol. Phys. 41(2), 279–286 (1998).
   PubMed Web of Science ®Google Scholar
• Esteban E, Villanueva N, Muniz I et al. Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized Phase II study. Invest. New Drugs 26(1), 67–74 (2008).
   PubMedGoogle Scholar
• Dimopoulou I, Efstathiou E, Samakovli A et al. A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment. Ann. Oncol. 15(8), 1250–1255 (2004).
   PubMed Web of Science ®Google Scholar
• Usui K, Katou Y, Furushima K, Tanaka Y, Tanai C, Ishihara T. Interstitial lung disease during chemotherapy combined with oxaliplatin and/or bevacizumab in advanced colorectal cancer patients. Jpn. J. Clin. Oncol. 41(4), 498–502 (2011).
   PubMedGoogle Scholar
• Trisolini R, Lazzari Agli L, Tassinari D et al. Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy. Eur. Respir. J. 18(1), 243–245 (2001).
   PubMed Web of Science ®Google Scholar
• Grahmann PR, Brauer M, Huter L, Sayer H, Neumann R, Braun RK. Respiratory failure and pulmonary fibrosis as a late side-effect after chemotherapy-induced by oxygen administration. Pneumologie 59(11), 763–769 (2005).
   PubMedGoogle Scholar
• Rudders RA. Bleomycin: pulmonary toxicity. Ann. Intern. Med. 78(4), 618 (1973).
   PubMedGoogle Scholar
• Hankins DG, Sanders S, MacDonald FM, Drage CW. Pulmonary toxicity recurring after a six week course of busulfan therapy and after subsequent therapy with uracil mustard. Chest 73(3), 415–416 (1978).
   PubMedGoogle Scholar
• Limper AH. Chemotherapy-induced lung disease. Clin. Chest Med. 25(1), 53–64 (2004).
   PubMed Web of Science ®Google Scholar
• Roychowdhury DF, Cassidy CA, Peterson P, Arning M. A report on serious pulmonary toxicity associated with gemcitabine-based therapy. Invest. New Drugs 20(3), 311–315 (2002).
   PubMed Web of Science ®Google Scholar
• Thomas AL, Cox G, Sharma RA et al. Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a Phase I/II dose-escalating study. Eur. J. Cancer 36(18), 2329–2334 (2000).
   PubMed Web of Science ®Google Scholar
• Yamada K, Ikehara M, Tanaka G, Nomura I, Oshita F, Noda K. Dose escalation study of paclitaxel in combination with fixed-dose irinotecan in patients with advanced non-small cell lung cancer (JCOG 9807). Oncology 66(2), 94–100 (2004).
   PubMed Web of Science ®Google Scholar
• Yamada M, Kudoh S, Hirata K, Nakajima T, Yoshikawa J. Risk factors of pneumonitis following chemoradiotherapy for lung cancer. Eur. J. Cancer 34(1), 71–75 (1998).
   PubMed Web of Science ®Google Scholar
• Liu X, Hong XN, Gu YJ, Wang BY, Luo ZG, Cao J. Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma. Leuk Lymphoma 49(9), 1778–1783 (2008).
   PubMed Web of Science ®Google Scholar
• Pepels MJ, Boomars KA, van Kimmenade R, Hupperets PS. Life-threatening interstitial lung disease associated with trastuzumab: case report. Breast Cancer Res. Treat 113(3), 609–612 (2009).
   PubMed Web of Science ®Google Scholar
• Vahid B, Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 133(2), 528–538 (2008).
   PubMed Web of Science ®Google Scholar
• Takahashi F, Takahashi K, Okazaki T et al. Role of osteopontin in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 24(3), 264–271 (2001).
   PubMed Web of Science ®Google Scholar
• Baron D, Mayo A, Kluger Y. Gemcitabine-induced chronic systemic capillary leak syndrome: a life-threatening disease. Clin. Oncol. (R. Coll. Radiol.) 18(1), 90–91 (2006).
   PubMedGoogle Scholar
• Schwaiblmair M, Behr W, Haeckel T, Markl B, Foerg W, Berghaus T. Drug induced interstitial lung disease. Open Respir. Med. J. 6, 63–74.
   PubMedGoogle Scholar
• Ozkan M, Dweik RA, Ahmad M. Drug-induced lung disease. Cleve Clin. J. Med. 68(9), 782–785, 789–795 (2001).
   PubMedGoogle Scholar
• Ryrfeldt A. Drug-induced inflammatory responses to the lung. Toxicol. Lett. 112–113, 171–176 (2000).
   Google Scholar
• Miettinen PJ, Warburton D, Bu D et al. Impaired lung branching morphogenesis in the absence of functional EGF receptor. Dev. Biol. 186(2), 224–236 (1997).
   PubMedGoogle Scholar
• Suzuki H, Aoshiba K, Yokohori N, Nagai A. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res. 63(16), 5054–5059 (2003).
   PubMed Web of Science ®Google Scholar
• Robbins RA, Jinkins PA, Bryan TW, Prado SC, Milligan SA. Methotrexate inhibition of inducible nitric oxide synthase in murine lung epithelial cells in vitro. Am. J. Respir. Cell Mol. Biol. 18(6), 853–859 (1998).
   PubMed Web of Science ®Google Scholar
• Sacchi S, Kantarjian HM, Freireich EJ et al. Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia. Leuk Lymphoma 35(5–6), 483–489 (1999).
   PubMed Web of Science ®Google Scholar
• Cooper JA Jr, Zitnik RJ, Matthay RA. Mechanisms of drug-induced pulmonary disease. Annu. Rev. Med. 39, 395–404 (1988).
   PubMed Web of Science ®Google Scholar
• Provenzano G. Chronic pulmonary toxicity of methotrexate and rheumatoid arthritis. Rheumatology (Oxford) 42(6), 802–803; author reply 803–804 (2003).
   PubMedGoogle Scholar
• Lateef O, Shakoor N, Balk RA. Methotrexate pulmonary toxicity. Expert Opin. Drug Saf. 4(4), 723–730 (2005).
   PubMedGoogle Scholar
• Hilliquin P, Renoux M, Perrot S, Puechal X, Menkes CJ. Occurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis. Br. J. Rheumatol. 35(5), 441–445 (1996).
   PubMedGoogle Scholar
• Kim YJ, Song M, Ryu JC. Mechanisms underlying methotrexate-induced pulmonary toxicity. Expert Opin. Drug Saf. 8(4), 451–458 (2009).
   PubMed Web of Science ®Google Scholar
• O'Driscoll BR, Hasleton PS, Taylor PM, Poulter LW, Gattameneni HR, Woodcock AA. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N. Engl. J. Med. 323(6), 378–382 (1990).
   PubMedGoogle Scholar
• Hartmann LC, Frytak S, Richardson RL, Coles DT, Cupps RE. Life-threatening bleomycin pulmonary toxicity with ultimate reversibility. Chest 98(2), 497–499 (1990).
   PubMedGoogle Scholar
• Gupta S, Mahipal A. Fatal pulmonary toxicity after a single dose of cyclophosphamide. Pharmacotherapy 27(4), 616–618 (2007).
   PubMedGoogle Scholar
• Maas KW, van der Lee I, Bolt K, Zanen P, Lammers JW, Schramel FM. Lung function changes and pulmonary complications in patients with stage III non-small cell lung cancer treated with gemcitabine/cisplatin as part of combined modality treatment. Lung Cancer 41(3), 345–351 (2003).
   PubMedGoogle Scholar
• Bell MR, Meredith DJ, Gill PG. Role of carbon monoxide diffusing capacity in the early detection of major bleomycin-induced pulmonary toxicity. Aust. N Z J. Med. 15(2), 235–240 (1985).
   PubMedGoogle Scholar
• Patel RB, Kotha SR, Sherwani SI et al. Pulmonary fibrosis inducer, bleomycin, causes redox-sensitive activation of phospholipase D and cytotoxicity through formation of bioactive lipid signal mediator, phosphatidic acid, in lung microvascular endothelial cells. Int. J. Toxicol. 30(1), 69–90 (2011).
   PubMedGoogle Scholar
• Ohbayashi M, Suzuki M, Yashiro Y et al. Induction of pulmonary fibrosis by methotrexate treatment in mice lung in vivo and in vitro. J. Toxicol. Sci. 35(5), 653–661 (2010).
   PubMed Web of Science ®Google Scholar
• Taus-Garcia A, Sanchez-Font A, Servitja-Tormo S, Pijuan L, Maiques-Llacer JM, Curull V. Organizing pneumonia associated with the use of trastuzumab. Arch. Bronconeumol. 46(8), 442–444 (2010).
   PubMedGoogle Scholar
• Frija J, Joly D, Knebelmann B, Dusser D, Burgel PR. Everolimus-related organizing pneumonia: a report establishing causality. Invest. New Drugs 30(3), 1244–1247 (2012).
   PubMed Web of Science ®Google Scholar
• Gould VE, Miller J. Sclerosing alveolitis induced by cyclophosphamide. Ultrastructural observations on alveolar injury and repair. Am. J. Pathol. 81(3), 513–530 (1975).
   PubMed Web of Science ®Google Scholar
• Cooper JA Jr., White DA, Matthay RA. Drug-induced pulmonary disease. Part 1: cytotoxic drugs. Am. Rev. Respir. Dis. 133(2), 321–340 (1986).
   PubMed Web of Science ®Google Scholar
• Tsai SM, Lin CY, Wu SH et al. Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms. Clin. Chim. Acta. 404(2), 160–165 (2009).
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355(24), 2542–2550 (2006).
   PubMed Web of Science ®Google Scholar
• Herbst RS, Sandler AB. Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab? Oncologist 9(Suppl. 1), 19–26 (2004).
   PubMedGoogle Scholar
• Trump DL, Ettinger DS, Feldman MJ, Dragon LH. 'Sarcoidosis' and sarcoid-like lesions. Their occurrence after cytotoxic and radiation therapy of testis cancer. Arch. Intern. Med. 141(1), 37–38 (1981).
   PubMedGoogle Scholar
• Bobbio-Pallavicini E, Valsecchi C, Tacconi F, Moroni M, Porta C. Sarcoidosis following beta-interferon therapy for multiple myeloma. Sarcoidosis 12(2), 140–142 (1995).
   PubMedGoogle Scholar
• Wilgenhof S, Morlion V, Seghers AC et al. Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor. Anticancer Res. 32(4), 1355–1359 (2012).
   PubMed Web of Science ®Google Scholar
• Franchi F, Seminara P, Gualdi GF. Lung pseudometastases due to vinblastine toxicity. Klin. Wochenschr. 62(21), 1047–1048 (1984).
   PubMedGoogle Scholar
• Cron RQ, Sherry DD, Wallace CA. Methotrexate-induced hypersensitivity pneumonitis in a child with juvenile rheumatoid arthritis. J. Pediatr. 132(5), 901–902 (1998).
   PubMedGoogle Scholar
• Mileshkin L, Prince HM, Rischin D, Zimet A. Severe interstitial pneumonitis following high-dose cyclophosphamide, thiotepa and docetaxel: two case reports and a review of the literature. Bone Marrow Transplant. 27(5), 559–563 (2001).
   PubMedGoogle Scholar
• White DA, Kris MG, Stover DE. Bronchoalveolar lavage cell populations in bleomycin lung toxicity. Thorax 42(7), 551–552 (1987).
   PubMed Web of Science ®Google Scholar
• Yousem SA, Lifson JD, Colby TV. Chemotherapy-induced eosinophilic pneumonia. Relation to bleomycin. Chest 88(1), 103–106 (1985).
   PubMed Web of Science ®Google Scholar
• Trojan A, Meier R, Licht A, Taverna C. Eosinophilic pneumonia after administration of fludarabine for the treatment of non-Hodgkin's lymphoma. Ann. Hematol. 81(9), 535–537 (2002).
   PubMedGoogle Scholar
• Rolston KV. The spectrum of pulmonary infections in cancer patients. Curr. Opin. Oncol. 13(4), 218–223 (2001).
   PubMed Web of Science ®Google Scholar
• Costabel U, Uzaslan E, Guzman J. Bronchoalveolar lavage in drug-induced lung disease. Clin. Chest Med. 25(1), 25–35 (2004).
   PubMed Web of Science ®Google Scholar
• Huang MS, Colby TV, Goellner JR, Martin WJ Jr. Utility of bronchoalveolar lavage in the diagnosis of drug-induced pulmonary toxicity. Acta. Cytol. 33(4), 533–538 (1989).
   PubMedGoogle Scholar
• Piciucchi S, Romagnoli M, Chilosi M et al. Prospective evaluation of drug-induced lung toxicity with high-resolution CT and transbronchial biopsy. Radiol. Med. 116(2), 246–263 (2011).
   PubMedGoogle Scholar
• Romagnoli M, Bigliazzi C, Casoni G et al. The role of transbronchial lung biopsy for the diagnosis of diffuse drug-induced lung disease: a case series of 44 patients. Sarcoidosis Vasc. Diffuse Lung. Dis. 25(1), 36–45 (2008).
   PubMed Web of Science ®Google Scholar
• Poletti V, Chilosi M, Olivieri D. Diagnostic invasive procedures in diffuse infiltrative lung diseases. Respiration 71(2), 107–119 (2004).
   PubMed Web of Science ®Google Scholar
• Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis. Rev. 18(4), 465–471 (1999).
   PubMed Web of Science ®Google Scholar
• O'Dwyer PJ, Weiss RB. Hypersensitivity reactions induced by etoposide. Cancer Treat Rep. 68(7–8), 959–961 (1984).
   PubMedGoogle Scholar
• Cersosimo RJ, Calarese P, Karp DD. Acute hypotensive reaction to etoposide with successful rechallenge: case report and review of the literature. DICP 23(11), 876–877 (1989).
   PubMedGoogle Scholar
• Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12(6), 713–718 (2007).
   PubMed Web of Science ®Google Scholar
• Carron PL, Cousin L, Caps T et al. Gemcitabine-associated diffuse alveolar hemorrhage. Intensive Care Med. 27(9), 1554 (2001).
   PubMedGoogle Scholar
• Alexandrescu DT, Dutcher JP, O'Boyle K, Albulak M, Oiseth S, Wiernik PH. Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma. Leuk Lymphoma 45(11), 2321–2325 (2004).
   PubMed Web of Science ®Google Scholar
• Heresi GA, Farver CF, Stoller JK. Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: case report and review of the literature. Respiration 76(4), 449–453 (2008).
   PubMed Web of Science ®Google Scholar
• Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM. A high rate of venous thromboembolism in a multi-institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer 95(8), 1629–1636 (2002).
   PubMed Web of Science ®Google Scholar
• Molloy RG, Welch GC, Drury JK, Abel BJ. Arterial thrombosis after chemotherapy with cisplatin, vinblastine and methotrexate. Br. J. Clin. Pract. 49(1), 50–51 (1995).
   PubMedGoogle Scholar
• Krishnan GS, Chaudhary V, Al-Janadi A, Ramanarayanan J, D’Silva KJ. BCNU toxicity presenting with a large pericardial and pleural effusion. Ann. Transplant 13(1), 44–47 (2008).
   PubMedGoogle Scholar
• Behrens RJ, Gulley JL, Dahut WL. Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide. Am. J. Ther. 10(3), 228–232 (2003).
   PubMedGoogle Scholar
• Kido H, Morizane C, Tamura T et al. Gemcitabine-induced pleuropericardial effusion in a patient with pancreatic cancer. Jpn. J. Clin. Oncol. 42(9), 845–850 (2012).
   PubMedGoogle Scholar
• Ishii Y, Shoji N, Kimura Y, Ohyashiki K. Prominent pleural effusion possibly due to imatinib mesylate in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Intern. Med. 45(5), 339–340 (2006).
   PubMedGoogle Scholar
• Brixey AG, Light RW. Pleural effusions due to dasatinib. Curr. Opin. Pulm. Med. 16(4), 351–356 (2010).
   PubMed Web of Science ®Google Scholar
• Schaap N, Raymakers R, Schattenberg A, Ottevanger JP, de Witte T. Massive pleural effusion attributed to high-dose cyclophosphamide during conditioning for BMT. Bone Marrow Transplant. 18(1), 247–248 (1996).
   PubMedGoogle Scholar
• Walden PA, Mitchell-Weggs PF, Coppin C, Dent J, Bagshawe KD. Pleurisy and methotrexate treatment. Br. Med. J. 2(6091), 867 (1977).
   PubMedGoogle Scholar
• Bergeron A, Rea D, Levy V et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am. J. Respir. Crit. Care Med. 176(8), 814–818 (2007).
   PubMed Web of Science ®Google Scholar
• Kido H, Morizane C, Tamura T et al. Gemcitabine-induced pleuropericardial effusion in a patient with pancreatic cancer. Jpn. J. Clin. Oncol. 42(9), 845–850 (2012).
   PubMedGoogle Scholar
• Kang MH, Ju JH, Kim HG et al. Thalidomide induced nonspecific interstitial pneumonia in patient with relapsed multiple myeloma. Korean J. Intern. Med. 25(4), 447–449 (2010).
   PubMedGoogle Scholar
• Kang W, Kim JS, Cho SH, Kim SK, Chang J, Park MS. Nonspecific interstitial pneumonitis after bortezomib and thalidomide treatment in a multiple myeloma patient. Yonsei Med. J. 51(3), 448–450 (2010).
   PubMedGoogle Scholar
• van Gorselen EO, Gerding MN. A crackling handshake. Pulmonary toxicity of bleomycin. Neth. J. Med. 69(2), 83–86 (2011).
   PubMedGoogle Scholar
• Koch H, Lesch R. Busulfan lung. Pulmonary fibrosis caused by Myleran. Med. Welt 27(7), 308–311 (1976).
   PubMedGoogle Scholar
• Refvem O. Fatal intraalveolar and interstitial lung fibrosis in chlorambucil-treated chronic lymphocytic leukemia. Mt. Sinai J. Med. 44(6), 847–851 (1977).
   PubMedGoogle Scholar
• Diaz-Gonzalez F, Castaneda-Sanz S, Lopez-Robledillo JC, Garcia-Vicuna R. Lung fibrosis in a patient with polyarteritis nodosa receiving cyclophosphamide therapy. J. Rheumatol. 19(2), 325–327 (1992).
   PubMedGoogle Scholar
• Verweij J, van Zanten T, Souren T, Golding R, Pinedo HM. Prospective study on the dose relationship of mitomycin C-induced interstitial pneumonitis. Cancer 60(4), 756–761 (1987).
   PubMed Web of Science ®Google Scholar
• Sotiriou C, van Houtte P, Klastersky J. Lung fibrosis induced by paclitaxel. Support Care Cancer 6(1), 68–71 (1998).
   PubMedGoogle Scholar
• Flaherty KR, Toews GB, Travis WD et al. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur. Respir. J. 19(2), 275–283 (2002).
   PubMed Web of Science ®Google Scholar
• Massin F, Fur A, Reybet-Degat O, Camus P, Jeannin L. Busulfan-induced pneumopathy. Rev. Mal. Respir. 4(1), 3–10 (1987).
   PubMedGoogle Scholar
• Vergnon JM, Boucheron S, Riffat J, Guy C, Blanc P, Emonot A. Interstitial pneumopathies caused by busulfan. Histologic, developmental and bronchoalveolar lavage analysis of 3 cases. Rev. Med. Interne. 9(4), 377–383 (1988).
   PubMedGoogle Scholar
• Correale P, Fulfaro F, Marsili S et al. Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer. Cancer Chemother. Pharmacol. 56(6), 563–568 (2005).
   PubMed Web of Science ®Google Scholar
• Tamura M, Saraya T, Fujiwara M et al. High-resolution computed tomography findings for patients with drug-induced pulmonary toxicity, with special reference to hypersensitivity pneumonitis-like patterns in gemcitabine-induced cases. Oncologist 18(4), 454–459 (2013).
   PubMed Web of Science ®Google Scholar
• Kudrik FJ, Rivera MP, Molina PL, Maygarden S, Socinski MA. Hypersensitivity pneumonitis in advanced non-small-cell lung cancer patients receiving gemcitabine and paclitaxel: report of two cases and a review of the literature. Clin. Lung Cancer 4(1), 52–56 (2002).
   PubMedGoogle Scholar
• Garrido M, O'Brien A, Gonzalez S, Clavero JM, Orellana E. Cryptogenic organizing pneumonitis during oxaliplatin chemotherapy for colorectal cancer: case report. Chest 132(6), 1997–1999 (2007).
   PubMed Web of Science ®Google Scholar
• Maxwell I. Letter: reversible pulmonary edema following cyclophosphamide treatment. JAMA 229(2), 137–138 (1974).
   PubMedGoogle Scholar
• Miller WT Jr., Shah RM. Isolated diffuse ground-glass opacity in thoracic CT: causes and clinical presentations. AJR Am. J. Roentgenol. 184(2), 613–622 (2005).
   PubMedGoogle Scholar
• Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir. Res. 13, 39 (2012).
   PubMed Web of Science ®Google Scholar
• White DA, Schwartz LH, Dimitrijevic S, Scala LD, Hayes W, Gross SH. Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001). J. Thorac. Oncol. 4(11), 1357–1363 (2009).
   PubMed Web of Science ®Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 22(11), 2184–2191 (2004).
   PubMed Web of Science ®Google Scholar
• Kharasch VS, Lipsitz S, Santis W, Hallowell JA, Goorin A. Long-term pulmonary toxicity of multiagent chemotherapy including bleomycin and cyclophosphamide in osteosarcoma survivors. Med. Pediatr. Oncol. 27(2), 85–91 (1996).
   PubMedGoogle Scholar
• Hansen SW, Groth S, Sorensen PG, Rossing N, Rorth M. Enhanced pulmonary toxicity in smokers with germ-cell cancer treated with cis-platinum, vinblastine and bleomycin: a long-term follow-up. Eur. J. Cancer Clin. Oncol. 25(4), 733–736 (1989).
   PubMedGoogle Scholar
• About I, Lauque D, Levenes H et al. Alveolar opacities and busulfan pneumonia. Rev. Mal. Respir. 10(1), 39–41 (1993).
   PubMedGoogle Scholar
• Spector JI, Zimbler H, Ross JS. Early-onset cyclophosphamide-induced interstitial pneumonitis. JAMA 242(26), 2852–2854 (1979).
   PubMedGoogle Scholar
• Mahendra P, Hood IM, Lee MA et al. Interstitial pneumonitis as a late complication of high dose therapy with cyclophosphamide/thiotepa and peripheral blood progenitor cell rescue for carcinoma of the breast. Clin. Oncol. (R. Coll. Radiol.) 8(3), 198–200 (1996).
   PubMedGoogle Scholar
• Leimgruber K, Negro R, Baier S et al. Fatal interstitial pneumonitis associated with docetaxel administration in a patient with hormone-refractory prostate cancer. Tumori 92(6), 542–544 (2006).
   PubMedGoogle Scholar
• Vahid B, Esmaili A. Erlotinib-associated acute pneumonitis: report of two cases. Can. Respir. J. 14(3), 167–170 (2007).
   PubMedGoogle Scholar
• Otton J, Hayward CS, Keogh AM, Glanville AR, Macdonald PS. Everolimus-associated pneumonitis in 3 heart transplant recipients. J. Heart Lung Transplant. 28(1), 104–106 (2009).
   PubMed Web of Science ®Google Scholar
• Exposito V, de Prada JA, Gomez-Roman JJ et al. Everolimus-related pulmonary toxicity in heart transplant recipients. J. Heart Lung Transplant. 27(7), 797–800 (2008).
   PubMed Web of Science ®Google Scholar
• Nagaria NC, Cogswell J, Choe JK, Kasimis B. Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis. J. Clin. Oncol. 23(10), 2423–2424 (2005).
   PubMed Web of Science ®Google Scholar
• Ieki R, Saitoh E, Shibuya M. Acute lung injury as a possible adverse drug reaction related to gefitinib. Eur. Respir. J. 22(1), 179–181 (2003).
   PubMed Web of Science ®Google Scholar
• Hoelzer KL, Harrison BR, Luedke SW, Luedke DW. Vinblastine-associated pulmonary toxicity in patients receiving combination therapy with mitomycin and cisplatin. Drug Intell. Clin. Pharm. 20(4), 287–289 (1986).
   PubMedGoogle Scholar
• Madarnas Y, Webster P, Shorter AM, Bjarnason GA. Irinotecan-associated pulmonary toxicity. Anticancer Drugs 11(9), 709–713 (2000).
   PubMed Web of Science ®Google Scholar
• Yoon JM, Rao U, Vassilopoulos PP, Ledesma E, Mittelman A. Interstitial pneumonitis associated with mitomycin C and DTIC: a case report. Med. Pediatr. Oncol. 9(1), 61–67 (1981).
   PubMedGoogle Scholar
• Webster M, Cairncross G, Gertler S, Perry J, Wainman N, Eisenhauer E. Phase II trial of SarCNU in malignant glioma: unexpected pulmonary toxicity with a novel nitrosourea: a Phase II trial of the national cancer institute of canada clinical trials group. Invest. New Drugs 23(6), 591–596 (2005).
   PubMedGoogle Scholar
• Ryan BR, Walters TR. Pulmonary fibrosis: a complication of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) therapy. Cancer 48(4), 909–911 (1981).
   PubMedGoogle Scholar
• Chan AK, Choo BA, Glaholm J. Pulmonary toxicity with oxaliplatin and capecitabine/5-fluorouracil chemotherapy: a case report and review of the literature. Onkologie 34(8–9), 443–446 (2011).
   PubMedGoogle Scholar
• Ruiz-Casado A, Garcia MD, Racionero MA. Pulmonary toxicity of 5-fluoracil and oxaliplatin. Clin. Transl. Oncol. 8(8), 624 (2006).
   PubMedGoogle Scholar
• Wong P, Leung AN, Berry GJ et al. Paclitaxel-induced hypersensitivity pneumonitis: radiographic and CT findings. AJR Am. J. Roentgenol. 176(3), 718–720 (2001).
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Reddy VV, Holbert JM, Belani CP. Pulmonary infiltrates following administration of paclitaxel. Chest 110(1), 289–292 (1996).
   PubMed Web of Science ®Google Scholar
• Maitland ML, Wilcox R, Hogarth DK et al. Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer. Lung Cancer 54(2), 243–245 (2006).
   PubMed Web of Science ®Google Scholar
• Edgerton CC, Gilman M, Roth BJ. Topotecan-induced bronchiolitis. South Med. J. 97(7), 699–701 (2004).
   PubMedGoogle Scholar
• Radzikowska E, Szczepulska E, Chabowski M, Bestry I. Organising pneumonia caused by transtuzumab (Herceptin) therapy for breast cancer. Eur. Respir. J. 21(3), 552–555 (2003).
   PubMed Web of Science ®Google Scholar
• Trump DL, Bartel E, Pozniak M. Nodular pneumonitis after chemotherapy for germ cell tumors. Ann. Intern. Med. 109(5), 431–432 (1988).
   PubMedGoogle Scholar